ClinicalTrials.gg
TerminatedNCT01957410Updated Jan 27, 2017Results posted

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

A Phase 2 interventional study of Ketamine and Placebo in Major Depressive Disorder, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
Clinical Team decision to terminate the study after the results from Cohort 1 did not support conducting Cohort 2.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Enrollment
68th of 89
13 · median 38
Started
2014
with 6 others
Phase 2
22 of 89
7 open now
Registered
20th of 89
by date
Lead sponsor
3 of 89
Janssen Research & Development, LLC

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 68th largest by enrollment, is one of 7 that started in 2014, is one of 22 in phase 2, and was the 20th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect changes in cortical plasticity in responders to a single IV infusion of ketamine as compared to non-responders.

Read the detailed description

This study will be conducted in patients with Major Depressive Disorder (MDD) and divided into 2 sequential cohorts. Cohort 1 will be conducted in 12 patients at a single center. For each patient, there will be up to 4 sequential phases: a screening phase of up to 6 weeks, an open-label treatment phase of up to 4 weeks, an optional open-label treatment phase of up to 1 week, and a follow-up phase of up to 1 week (if applicable). Cohort 2 will be conducted in 20 patients and will be a multicenter, double-blind (neither physician nor patient knows the treatment that the patient receives), randomized (the study drug is assigned by chance), placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) design. For each patient, there will be up to 4 sequential phases: a screening phase of up to 6 weeks, a double-blind treatment phase of up to 4 weeks, an optional open-label treatment phase of up to 1 week, and a follow-up phase of up to 1 week (if applicable). The total study duration for each patient will be maximally about 12 weeks. Participant safety will be monitored throughout the study.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Ketamine
  • Evoked potentials
  • Somatosensory evoked potentials
  • Motor evoked potentials
  • Cortical plasticity
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be medically stable
  • Patient must meet - Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI)
  • Patient must have had an inadequate response to at least 2 antidepressants, one of which is in the current episode of depression
  • Patient must have an Inventory of Depressive Symptomatology 30-item Clinician-rated (IDS-C30) total score ≥ 34 at Screening and Day -1
  • Women must be , surgically sterile, or, if heterosexually active, practicing a highly effective method of
  • Men who are heterosexually active with a woman of must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Patient has current signs and/or symptoms of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbances
  • Patient has a primary diagnosis of current (active) generalized anxiety disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa
  • Patient has a current diagnosis of bipolar disorder, mental retardation, or cluster b personality disorder (e.g., borderline personality disorders, antisocial personality disorder, etc)
  • Patient has a current or prior diagnosis of a psychotic disorder or MDD with psychosis
  • Patient has not responded to treatment with electroconvulsive therapy (ECT) in the current episode of depression
  • Patient has suicidal ideation with intent to act, or has homicidal ideation/intent, during Screening phase per Investigator's clinical judgment
  • Patient has any significant primary sleep disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Ketamine Intravenous (IV)

    Patients will receive a single IV dose of ketamine given as a continuous infusion.

    Drug: Ketamine

  • Placebo comparator
    Placebo Intravenous (IV)

    Patients will receive a single IV dose of placebo given as a continuous infusion.

    Drug: Placebo

Interventions

  • During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.

  • DrugPlacebo

    During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.

06

What researchers measure

Primary outcomes

  1. Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Somatosensory Evoked Potential (SEPs) Amplitudes at 4 Hours Postdose on Day 1

    SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 64-channel EEG system at baseline (predose) and regularly after study drug administration. The change from baseline was calculated as post-baseline value minus baseline value for each participant. Since the number of participants at baseline differ from the number of participants at post-baseline measure (that is \[i.e.\] not all baseline values are paired), the mean change is not equal to the difference between the means at the two time points.

    Time frame: Baseline and Day 1 (4 hours postdose)

  2. Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Motor Evoked Potential (MEPs) Amplitudes at 4 Hours Postdose on Day 1

    MEPs are generated when stimulation of the brain on the motor cortex (with Transcranial Magnetic Stimulation \[TMS\]) causes the spinal cord and peripheral muscles to produce neuroelectrical signals. MEPs are typically measured in the hand muscles. The Motor Evoked Response to Transcranial Magnetic Stimulation (TMS MEPs) was evaluated at baseline and regularly after study drug administration. Intracortical inhibition and facilitation was also evaluated using TMS. A figure-of-eight coil with external loop diameters of 9 cm was used to elicit motor responses in the contralateral first dorsal interosseus.

    Time frame: Baseline and Day 1 (4 hours postdose)

07

Results

Posted Jan 27, 2017
Limitations and caveats
Study was planned as open label treatment phase (Cohort 1) and double blind treatment phase (Cohort 2). However, study was terminated after completion of Cohort 1.

Participant flow

A total of 13 participants were enrolled, treated and completed the study.

Open Label
Participant flow — Open Label
MilestoneKetamine IV 0.5mg/kg
Started13
Completed13
Not completed0
Optional Open Label
Participant flow — Optional Open Label
MilestoneKetamine IV 0.5mg/kg
Started13
Completed13
Not completed0

Outcome measures

PrimaryComparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Somatosensory Evoked Potential (SEPs) Amplitudes at 4 Hours Postdose on Day 1

SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 64-channel EEG system at baseline (predose) and regularly after study drug administration. The change from baseline was calculated as post-baseline value minus baseline value for each participant. Since the number of participants at baseline differ from the number of participants at post-baseline measure (that is \[i.e.\] not all baseline values are paired), the mean change is not equal to the difference between the means at the two time points.

Time frame:
Baseline and Day 1 (4 hours postdose)
Reported as:
Mean · millivolts (mV)
Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Somatosensory Evoked Potential (SEPs) Amplitudes at 4 Hours Postdose on Day 1
millivolts (mV)Ketamine IV 0.5mg/kg
Responders: Baseline (n=9)1.83 ± 1.13
Responders: Day 1, 4 Hours (n=6)2.58 ± 1.24
Responders: Change from Baseline (n=6)0.47 ± 1.68
Non-Responders: Baseline (n=4)1.70 ± 1.10
Non-Responders: Day 1, 4 Hours (n=3)1.84 ± 1.48
Non-Responders: Change from Baseline (n=3)0.47 ± 0.43
PrimaryComparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Motor Evoked Potential (MEPs) Amplitudes at 4 Hours Postdose on Day 1

MEPs are generated when stimulation of the brain on the motor cortex (with Transcranial Magnetic Stimulation \[TMS\]) causes the spinal cord and peripheral muscles to produce neuroelectrical signals. MEPs are typically measured in the hand muscles. The Motor Evoked Response to Transcranial Magnetic Stimulation (TMS MEPs) was evaluated at baseline and regularly after study drug administration. Intracortical inhibition and facilitation was also evaluated using TMS. A figure-of-eight coil with external loop diameters of 9 cm was used to elicit motor responses in the contralateral first dorsal interosseus.

Time frame:
Baseline and Day 1 (4 hours postdose)
Reported as:
Mean · mV
Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Motor Evoked Potential (MEPs) Amplitudes at 4 Hours Postdose on Day 1
mVKetamine IV 0.5mg/kg
Responders: Baseline (n=9)0.874 ± 0.710
Responders: Day 1, 4 hour (H) (n=9)1.052 ± 0.867
Responders: Change from Baseline (n=9)0.179 ± 0.765
Non-Responders: Baseline (n=4)1.257 ± 1.055
Non-Responders: Day 1, 4H (n=4)1.197 ± 1.067
Non-Responders: Change from Baseline (n=4)-0.060 ± 0.088

Adverse events

Collected over Up to 1 week after the last dose administration (6 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine IV 0.5mg/kg—0/13 (0%)10/13 (76.9%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventKetamine IV 0.5mg/kg
HeadacheNervous system disorders4/13
Infusion site bruisingGeneral disorders2/13
Panic attackPsychiatric disorders2/13
NauseaGastrointestinal disorders1/13
Bacterial vaginosisInfections and infestations1/13
Oral herpesInfections and infestations1/13
Respiratory tract infectionInfections and infestations1/13
Urinary tract infectionInfections and infestations1/13
MyalgiaMusculoskeletal and connective tissue disorders1/13
Paranasal sinus discomfortRespiratory, thoracic and mediastinal disorders1/13

Baseline characteristics

Baseline analysis population included all participants who were received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ketamine IV 0.5mg/kg
Mean40.9 ± 11.45
Gender
Gender(Participants)Ketamine IV 0.5mg/kg
Female9
Male4
Region of Enrollment
Region of Enrollment(participants)Ketamine IV 0.5mg/kg
USA13
08

Study locations

1 site
  • Durham, North Carolina, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2013
First posted
Oct 8, 2013
Start
Feb 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Jan 27, 2017
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01957410
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Feb 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Jan 27, 2017
Last update
Jan 27, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion